Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
"A comprehensive set of samples in various diseases. The resource consists of DNA samples from 16 diseases (Type I diabetes, Type II diabetes, Asthma, Colorectal Cancer, Breast Cancer, Prostate Cancer, Alzheimer's disease, Parkinson's disease... More
Novel gene scanning methodology More
Leverage the First Known Schizophrenia Susceptibility Gene for New Treatments & Diagnostics More
Mismatch-targeted transposition of Mu: a new strategy to map genetic polymorphism. More
PharmiGene Inc.:Technology associated with the PG 5801 DNA Detection Kit and the PG 5801 FastGel Kit
Technology associated with PharmiGene's PG 5801 DNA Detection Kit and the PG 5801 FastGel Kit, kits to determine the risk of Allopurinol-induced severe cutaneous adverse reaction (SCAR). More
PharmiGene Inc.: Technology associated with the PG 1502 DNA Detection Kit and the PG1502 FastGel Kit
Technology associated with PharmiGene's PG 1502 DNA Detection Kit and the PG1502 FastGel Kit, kits to determine the risk of Carbamazepine-induced SJS/TEN adverse drug reaction (ADR). More
Technology associated with PharmiGene's Warfarin Dose Prediction Kit, a kit to determine the appropriate Warfarin dosage administration based on the presence of the VKORC1-1639 and CYP2C9 genes. More
Your selection
Browse By
- Therapeutic target
- Birth defects
- Blood clotting disorders
- Fabry's disease
- Gaucher's disease
- Genetic disorder (other)
- Hunter's syndrome
- Huntington's disease
- Kawasaki disease
- Klinefelter's syndrome
- Phenylketonuria
- Severe combined immunodeficiency
- Turner's syndrome
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us